SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 25, 2003
HAEMONETICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Massachusetts 1-10730 04-2882273
------------- ------- ----------
(State or other jurisdiction of (Commission File (IRS Employer
incorporation or organization) Number) Identification Number)
400 Wood Road
Braintree, MA 02184
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code (781) 848-7100
Item 5. Other Events and Regulation FD Disclosure
- ------- -----------------------------------------
On August 25, 2003, Haemonetics Corporation (the "Company") announced the
election of Lawrence C. Best, Senior Vice President and Chief Financial
Officer of Boston Scientific Corporation, to its Board of Directors. The
election was effective as of August 22, 2003.
Item 7. Financial Statements and Exhibits.
- ------- ----------------------------------
(c) Exhibits.
---------
99.1 Press Release of the Company dated August 25, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
Date: August 25, 2003 By: /s/Ronald J. Ryan
------------------
Ronald J. Ryan, Senior Vice
President and Chief Financial
Officer
3
Exhibit 99.1
------------
FOR RELEASE: CONTACT:
Date: August 25, 2003 Lisa Lopez
Time: 10:00 a.m. Tel. (781) 356-9457
Alternate Tel. (617) 320-2401
fallon@haemonetics.com
----------------------
Haemonetics Elects Boston Scientific CFO to Its Board of Directors
------------------------------------------------------------------
BRAINTREE, MA, August 25, 2003 - Haemonetics Corporation (NYSE:HAE) today
announced that Lawrence C. Best, Senior Vice President and Chief Financial
Officer of Boston Scientific Corporation, has been elected to the
Haemonetics Board of Directors. The election was effective as of August
22, 2003.
Mr. Best has served as Senior Vice President and Chief Financial Officer
for Boston Scientific since 1992. Prior to his work with Boston
Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young,
where he specialized in serving multinational companies in the high
technology and life sciences fields. He also served a two-year fellowship
at the Securities and Exchange Commission from 1979 to 1981 and a one-year
term as a White House-appointed Presidential Exchange Executive in
Washington, D.C. Mr. Best also serves as a member of the Board of
Directors of Biogen, Inc.
Ronald A. Matricaria, Chairman of Haemonetics, said, "Larry brings an
impressive record of financial discipline and a strong understanding of the
issues facing medical device companies. He has been a key member of the
Boston Scientific executive team that is credited with building one of the
market leading companies in the medical device industry. We are delighted
he agreed to serve on our board, and as a member of the Audit Committee."
Haemonetics is a global company engaged in the design, manufacture and
worldwide marketing of automated blood processing systems. These systems
address important medical markets: surgical blood salvage, blood component
collection, plasma collection, and blood component safety. To learn more
about Haemonetics' products and markets, visit the Company's web site at
http://www.haemonetics.com.